NEXT NUM ROWS=1
Sunday, November 28th, 2021

 

Next
A full text version of this article is available.
To access article obtain online access here or login
 
Title:
Effect of Intracoronary Application of Nicorandil and Tirofiban on No-Reflow Phenomenon in Patients with Acute Coronary Syndrome
Authors:  Feng Yan, M.M., Qian Wang, M.M., Junnan Li, M.M., and Hui Lv, M.D.
  Objective: To investigate the effects of nicorandil and tirofiban on no-reflow and postoperative outcome in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention.
Study Design:
A total of 438 patients with ACS diagnosed by the second Hospital of Shanxi Medical University from January 2019 to December 2020 were divided into two groups: nicorandil group (n=223) and tirofiban group (n=215). The nicorandil group was injected with 2 mg nicorandil 2 mm before coronary occlusion before balloon dilation, and the tirofiban group received 10 μg/kg intravenous injection during operation. Measurement of thrombolysis grade (thrombolysis in myocardial infarction [TIMI]), corrected TIMI frame count, and major adverse vascular events were recorded 30 days after operation in patients with ACS.
Results:
Both nicorandil and tirofiban could improve the TIMI grade, and TIMI grade 3 blood flow was obtained in 190 cases (85.2%) and 175 cases (81.4%), respectively. There was no significant difference in the incidence of major adverse cardiac events (14.3% vs. 13.5%, score 0.13).
Conclusion:
Intracoronary use of nicorandil in patients with ACS can improve coronary perfusion, but the improvement of prognosis needs further study.
Keywords:  coronary perfusion, myocardial infarction, nicorandil, no-reflow phenomenon, percutaneous coronary intervention, repercussion
   
   
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from